| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FN3K |
| Uniprot No | Q9H479 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-309aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMEQLLRA ELRTATLRAF GGPGAGCISE GRAYDTDAGP VFVKVNRRTQ ARQMFEGEVA SLEALRSTGL VRVPRPMKVI DLPGGGAAFV MEHLKMKSLS SQASKLGEQM ADLHLYNQKL REKLKEEENT VGRRGEGAEP QYVDKFGFHT VTCCGFIPQV NEWQDDWPTF FARHRLQAQL DLIEKDYADR EARELWSRLQ VKIPDLFCGL EIVPALLHGD LWSGNVAEDD VGPIIYDPAS FYGHSEFELA IALMFGGFPR SFFTAYHRKI PKAPGFDQRL LLYQLFNYLN HWNHFGREYR SPSLGTMRRL LK |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FN3K重组蛋白的3篇参考文献概览：
1. **文献名称**：*"Cloning and expression of human fructosamine-3-kinase (FN3K)"*
**作者**：Szwergold BS, et al.
**摘要**：该研究首次报道了人源FN3K基因的克隆，并在大肠杆菌中成功表达重组蛋白，证实其能够催化果糖胺的磷酸化反应，为后续功能研究奠定基础。
2. **文献名称**：*"Fructosamine 3-kinase is involved in the degradation of glycated proteins in vivo"*
**作者**：Delpierre G, Van Schaftingen E.
**摘要**：通过重组FN3K蛋白的体外实验，揭示了其通过磷酸化修饰降解糖化蛋白的机制，表明其在调节细胞糖基化水平中的关键作用。
3. **文献名称**：*"Crystal structure of fructosamine 3-kinase from Homo sapiens"*
**作者**：Fortpied J, et al.
**摘要**：解析了人源FN3K重组蛋白的晶体结构，阐明了其活性位点与底物结合模式，为开发针对糖尿病并发症的抑制剂提供结构基础。
4. **文献名称**：*"Functional characterization of recombinant FN3K in diabetic model systems"*
**作者**：Nagao R, et al.
**摘要**：利用重组FN3K蛋白在糖尿病细胞模型中验证其减少晚期糖基化终产物(AGEs)的功能，提示其潜在治疗应用价值。
(注：以上文献为模拟概括，实际文献需通过数据库如PubMed检索确认。)
**Background of FN3K Recombinant Protein**
Fructosamine 3-kinase (FN3K) is an enzyme involved in the detoxification of glycation damage, a process linked to metabolic disorders such as diabetes. It catalyzes the phosphorylation of fructosamines, unstable intermediates formed during non-enzymatic glycation of proteins, to produce fructosamine 3-phosphates. These phosphorylated derivatives are subsequently degraded, reducing the accumulation of advanced glycation end-products (AGEs), which contribute to diabetic complications and cellular dysfunction. FN3K is ubiquitously expressed, with high activity in tissues prone to glycation stress, including the liver, kidneys, and red blood cells.
Recombinant FN3K protein is engineered using biotechnological methods, typically by cloning the FN3K gene into expression vectors (e.g., bacterial or mammalian systems) to produce purified, functional enzyme for research or therapeutic applications. Its recombinant form retains catalytic activity, enabling studies on glycation repair mechanisms, enzyme kinetics, and interactions with substrates or inhibitors. This protein is pivotal in diabetes research, as dysregulated glycation is a hallmark of hyperglycemia. By modulating FN3K activity, researchers aim to develop strategies to mitigate AGE-related pathologies, such as nephropathy, retinopathy, and cardiovascular diseases.
Additionally, FN3K recombinant protein serves as a tool for diagnostic assays, screening potential drugs, or investigating genetic variants affecting enzyme function. Its role in erythrocyte homeostasis—preventing hemoglobin glycation—has spurred interest in therapies for diabetic hematologic complications. Despite progress, challenges remain in understanding tissue-specific regulation and translating findings into clinical interventions. Overall, FN3K recombinant protein bridges mechanistic insights into glycation biology and the development of targeted therapies for metabolic diseases.
×
